Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.69 |
| ▸ | AKR1C3 | P42330 | 13/20 | 0.67 |
| ▸ | AKR1C2 | P52895 | 13/20 | 0.67 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.67 |
| ▸ | CDC42 | P60953 | 1/20 | 0.67 |
| ▸ | RAC1 | P63000 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.67 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10025981 | 1.00 | AKR1B1 (0.69) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL1217681 | 1.00 | AKR1B1 (0.69) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL4679446 | 1.00 | AKR1B1 (0.69) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL30717241 | 1.00 | AKR1B1 (0.69) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| Hydrochloric Acid SCHEMBL27401798 | 0.98 | AKR1B1 (0.67) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL503391 | 0.93 | AKR1B1 (0.61) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL11470486 | 0.90 | AKR1C3 (0.69) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| Naproxen SCHEMBL23753934 | 0.89 | AKR1C3 (0.88) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| Ammonia Solution, Strong SCHEMBL11721423 | 0.89 | AKR1C3 (0.67) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL15695558 | 0.89 | UGT2B7 (0.60) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107935874-A | A kind of synthetic method of (R) 3 amino 3 (2 naphthyl) propionic acid | 康化（上海）新药研发有限公司 | 2018-04-20 | — | — | CN | claimed |
| CN-119320366-A | Substituted naphthalene methyl oxadiazole-aniline compound and application thereof | 中国医学科学院药物研究所 | 2025-01-17 | — | — | CN | disclosed |
| US-20240409598-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH INC (US) | 2024-12-12 | — | — | US | disclosed |
| EP-4249470-B1 | METHOD FOR PREPARING ALPHA-AMINO ACIDS | PHILIPPS UNIV MARBURG (DE) | 2024-11-13 | — | — | EP | disclosed |
| US-20240352073-A1 | BICYCLIC PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH INC (US) | 2024-10-24 | — | — | US | disclosed |
| US-20240200049-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR MAKING POLYPEPTIDES WITH MANY INSTANCES OF NONSTANDARD AMINO ACIDS | YALE UNIVERSITY | 2024-06-20 | — | — | US | disclosed |
| EP-4332089-A1 | METHOD FOR PREPARING AMINO ACIDS | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2024-03-06 | — | — | EP | disclosed |
| WO-2024010529-A1 | PRODUCTION OF ENANTIOPURE ALCOHOLS, AMINES AND ACIDS FROM RACEMIC EPOXIDES BY CASCADE BIOTRANSFORMATION INVOLVING EPOXIDE ISOMERIZATION AND DYNAMIC KINETIC RESOLUTION | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2024-01-11 | — | — | WO | disclosed |
| WO-2023191721-A2 | PRODUCTION OF ENANTIOPURE ALCOHOLS, AMINES AND ACIDS FROM ALKENES BY CASCADE BIOTRANSFORMATION INVOLVING 1,2-METHYL SHIFT | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2023-10-05 | — | — | WO | disclosed |
| EP-4249470-A1 | METHOD FOR PREPARING ALPHA-AMINO ACIDS | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2023-09-27 | — | — | EP | disclosed |
| WO-2015120287-A2 | COMPOSITIONS AND METHODS OF USE THEREOF FOR MAKING POLYPEPTIDES WITH MANY INSTANCES OF NONSTANDARD AMINO ACIDS | YALE UNIVERSITY (US) | 2015-08-13 | — | — | WO | disclosed |
| US-7981645-B2 | Enzymatic asymmetric decarboxylation of disubstituted malonic acids | BIOSPRING GMBH (DE) | 2011-07-19 | — | — | US | disclosed |
| CN-102083793-A | Protease inhibitors | AMBRILIA BIOPHARMA INC | 2011-06-01 | — | — | CN | disclosed |
| US-20100144010-A1 | Enzymatic Asymmetric Decarboxylation of Disubstituted Malonic Acids | BIOSPRING GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| WO-2009055002-A1 | COMBINED INHIBITORS OF CYCLOOXYGENASE AND SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) (VASCULAR ADHESION PROTEIN, VAP-1) | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2009-04-30 | — | — | WO | disclosed |
| CN-101056635-A | Niacin receptor agonists, compositions containing such compounds and methods of treatment | MERCK & CO INC (US) | 2007-10-17 | — | — | CN | disclosed |
| CN-1128874-C | Rhodococcus sp.D12 and its culture method and application | SHANGHAI INST ORGANIC CHEM (CN) | 2003-11-26 | — | — | CN | disclosed |
| CN-1354740-A | Pharmaceutical compounds | NICOX SA (FR) | 2002-06-19 | — | — | CN | disclosed |
| CN-1291648-A | Rhodococcus sp.D12 and its culture method and application | SHANGHAI INST ORGANIC CHEM (CN) | 2001-04-18 | — | — | CN | disclosed |
| CN-1251523-A | Sulfonamide derivatives | LILLY CO ELI (US) | 2000-04-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240352073-A1 | BICYCLIC PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL1RN, IL17A | AKR1B1 2109/4885AKR1C3 562/4885AKR1C2 1141/4885 |
| US-20240409598-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL1RN, IL36G | AKR1B1 1695/4885AKR1C3 587/4885AKR1C2 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.